Startseite

Organisationen & Science Board

Netzwerke

SCHWEIZERISCHE ARBEITSGEMEINSCHAFT FUR KLINISCHE KREBSFORSCHUNG
SAKK.CH

EUROPEAN THORACIC ONCOLOGY PLATFORM (ETOP)

WWW.ETOP-EU.ORG

THE NATIONAL CENTER OF COMPETENCE IN RESEARCH (NCCR) IN MOLECULAR ONCOLOGY

NCCR-ONCOLOGY.CH

ONKOLOGISCHE REHABILITATION

ONCOREHA.CH

PALLIATIVE CARE

PALLIATIVE.CH

SCHWEIZERISCHE GESELLSCHAFT FÜR PSYCHOONKOLOGIE

PSYCHOONKOLOGIE.CH

News

First-line NIVO + CT vs CT alone for advanced gastric, gastro-oesophageal junction, & oesophageal adenocarcinoma (CheckMate 649): a new standard

07-07-2021 12:45
Weiterlesen ...
Blood test for early detection of cancer: final study results support screening use. Test can detect over 50 types of cancer, often before symptoms show

24-06-2021 23:01
Weiterlesen ...
Swissmedic Approves TEPMETKO® a Once-Daily Targeted Therapy for NSCLC with a METex14 Skipping Mutation1

23-06-2021 11:32
Weiterlesen ...
Isatuximab + carfilzomib–dexamethasone: a new standard of care for R/R MM

21-06-2021 08:58
Weiterlesen ...
Lehrvideo zur Entfernung von Bauchspeicheldrüsentumoren mittels Robotik

16-04-2021 08:42
Weiterlesen ...
New Standard of Care: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

03-04-2021 08:40
Weiterlesen ...
Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer

26-03-2021 09:58
Go to the ELCC/ESMO 2021 PRESS RELEASE
SECOND DRUG TARGETING KRAS G12C SHOWS BENEFIT IN MUTATED NON-SMALL-CELL LUNG CANCER

25-03-2021 17:15
Go to the ELCC/ESMO 2021 PRESS RELEASE
ASCO Remembers Breast Cancer Drug Development Pioneer Dr. José Baselga

24-03-2021 09:47
ASCO and the oncology community are deeply saddened by the passing of José Baselga, MD, PhD, FASCO, on March 21, 2021, at age 61. Dr. Baselga died of Creutzfeldt-Jakob disease, a rare fatal neurodegenerative disorder, according to his family. READ MORE

News

First-line NIVO + CT vs CT alone for advanced gastric, gastro-oesophageal junction, & oesophageal adenocarcinoma (CheckMate 649): a new standard

Blood test for early detection of cancer: final study results support screening use. Test can detect over 50 types of cancer, often before symptoms show

Swissmedic Approves TEPMETKO® a Once-Daily Targeted Therapy for NSCLC with a METex14 Skipping Mutation1

Isatuximab + carfilzomib–dexamethasone: a new standard of care for R/R MM

Lehrvideo zur Entfernung von Bauchspeicheldrüsentumoren mittels Robotik

New Standard of Care: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer

SECOND DRUG TARGETING KRAS G12C SHOWS BENEFIT IN MUTATED NON-SMALL-CELL LUNG CANCER

ASCO Remembers Breast Cancer Drug Development Pioneer Dr. José Baselga

Newsletter